Mirtazapina Stada (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release. It also antagonises 5‑HT2 and 5‑HT3 receptors while acting as a 5‑HT1A agonist, leading to higher serotonin and norepinephrine levels in the brain and helping to improve mood.

The appropriate dose of Mirtazapina Stada is determined by the prescribing clinician based on the individual’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, which differs from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This profile often results in pronounced sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtazapina Stada should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency.

The medication is taken orally, usually once daily in the evening, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless otherwise instructed.

Serious risks include the potential for suicidal thoughts, especially at treatment initiation, agranulocytosis or severe neutropenia, seizures, and significant hepatic dysfunction. Patients should be monitored closely for any signs of these adverse events and seek immediate medical attention if they occur.

Mirtazapina Stada is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently receiving monoamine oxidase inhibitors. Caution is also advised for individuals with severe hepatic impairment, uncontrolled seizures, or a history of agranulocytosis.